Suppr超能文献

病毒载量检测不到情况下的丙型肝炎相关混合性冷球蛋白血症性肾小球肾炎:羟氯喹成功治疗及文献综述

Hepatitis C associated mixed cryoglobulinemia glomerulonephritis in the setting of undetectable viral load: successful treatment with hydroxychloroquine and review of the literature.

作者信息

Shweikeh Faris, Torres Yaritza, Khan Khadeja, Mouchli Mohamad, Singh Inderprit

机构信息

Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA.

College of Medicine, Northeast Ohio Medical University, Rootstown, OH, USA.

出版信息

Immunol Res. 2025 Feb 21;73(1):55. doi: 10.1007/s12026-025-09608-7.

Abstract

There are an estimated 58 million cases of Hepatitis C (HCV) worldwide. Approximately 38-76% of individuals can develop extrahepatic manifestations such as mixed cryoglobulinemia (MC). Importantly, the appearance of symptoms due to MC is linked by detectable HCV RNA. A 38-year-old male with remote history of HCV infection diagnosed 8 years prior presented to the emergency department with subacute renal failure with proteinuria, hematuria, and WBC/RBC casts. Biopsy confirmed acute proliferative, non-crescentic, inflammatory glomerulonephritis. He also had new onset cryoglobulinemia. His HCV RNA was low-grade and liver function tests were all within the normal range. A liver biopsy showed signs of chronic hepatitis with mildly active portal fibrosis. The MC was cleared with steroids and a re-measured HCV RNA quantitative was negative. Seven months later, he was readmitted with glomerulonephritis and elevated MC. However, the patient's HCV viral load was undetectable. The patient underwent 6 rounds of plasmapheresis and 6 doses of Rituximab were given with suppression of cryoglobulin to nil. A month later, the MC levels rose again, while the viral load remained undetectable with the possibility of spontaneous remission. After initiation of maintenance hydroxychloroquine, his GFR improved to normal over the next 2 years. Multiple theories have been suggested for the phenomenon including presence of residual virus and lymphoproliferation effects. Hydroxychloroquine could be a successful option, though future studies should corroborate our outcome.

摘要

据估计,全球丙型肝炎(HCV)病例达5800万例。约38%-76%的个体可出现肝外表现,如混合性冷球蛋白血症(MC)。重要的是,MC所致症状的出现与可检测到的HCV RNA相关。一名38岁男性,8年前被诊断为HCV感染,现因亚急性肾衰竭伴蛋白尿、血尿及白细胞/红细胞管型就诊于急诊科。活检证实为急性增生性、非新月体性炎症性肾小球肾炎。他还新发冷球蛋白血症。其HCV RNA水平较低,肝功能检查均在正常范围内。肝脏活检显示慢性肝炎迹象,伴有轻度活动性门脉纤维化。MC经类固醇治疗后清除,重新检测的HCV RNA定量为阴性。7个月后,他因肾小球肾炎和MC升高再次入院。然而,患者的HCV病毒载量检测不到。患者接受了6轮血浆置换,并给予6剂利妥昔单抗,冷球蛋白被抑制至零。1个月后,MC水平再次升高,而病毒载量仍检测不到,有可能自发缓解。开始维持性羟氯喹治疗后,其肾小球滤过率在接下来的2年中恢复正常。对于这一现象提出了多种理论,包括残留病毒的存在和淋巴细胞增殖效应。羟氯喹可能是一种成功的选择,不过未来的研究应证实我们的结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验